GIPS-IV trial

Preservation of myocardial function after myocardial infarction

2 Current vacancy for GIPS-IV trial

Physician-Scientist (Ischemic and Valvular Disease)

Project: GIPS-IV trial, Early Synergy Research line: Ischemic Heart Diseases

More about this vacancy

Bachelor and Master students

Project: BIOSTAT-CHF, Early Synergy, GIPS-IV trial, Adiposity in Heart Failure with Preserved Ejection Fraction, iPHORECAST, KETONE-HF, RACE‐8‐HF, RED-CVD, SECRETE-HF, Selenium and Heart Failure, STOP-HF, PLN cardiomyopathy, AF RISK, APAF-CRT, RACE 9, RASTA AF Research line: Heart Failure, Ischemic Heart Diseases, Experimental Cardiology, Atrial Fibrillation

More about this vacancy

In the past decades, as a result of advances in pharmacological, reperfusion and preventive strategies, prognosis of patients with ST-elevated myocardial infarction has substantially improved and mortality has decreased. However, permanent myocardial injury related to the ischemia and subsequent reperfusion is still observed in the vast majority of patients and harbors a risk of heart failure development. Although many advances have been made, there is no specific treatment that targets myocardial reperfusion injury, which is considered to be a paradoxical form of myocardial damage that occurs as a result of the restoration of vessel patency. Reducing myocardial reperfusion injury is expected to further decrease infarct size, decreasing adverse cardiac remodeling and improving cardiac function as well as clinical outcome.

H2S has been shown to protect from (myocardial) ischemia reperfusion injury in various experimental models. It reduces infarct size and attenuates the loss of cardiac function. Inhibition of leukocyte endothelial cell interactions, neutralization of reactive oxygen species (ROS) and the reduction of apoptotic signaling were all suggested as mechanisms underlying the cardioprotective effect of H2S. The H2S donor sodium thiosulfate (STS) is already administered to humans for many years for calciphylaxis and cyanide poisoning. Recently, we demonstrated that STS is well tolerated in patients presenting with acute coronary syndrome.

The GIPS-IV study, designed by our group, will be the first study to determine the efficacy of a H2S-donor to reduce myocardial infarct size in patients with ST-elevated myocardial infarction. Currently, recruitment has completed. First results are expected fall 2021.

“We are good at restoring the coronary blood flow via percutaneous interventions. However, usually the oxygen shortage has already caused damage to the cardiac muscle. In our hospital we are testing new strategies to improve the response of the heart to oxygen shortages.”

People involved

Principal investigator

Pim van der Harst

Cardiologist
Team

Erik Lipsic

Cardiologist

Gabija Pundziute-Do Prado

Cardiologist

Paulien van Dorp

Physician-scientist

Marie-Sophie de Koning

Physician-scientist

Press & publications

Safety and Tolerability of Sodium Thiosulfate in Patients with an Acute Coronary Syndrome Undergoing Coronary Angiography: A Dose-Escalation Safety Pilot Study (SAFE-ACS)

Safety and Tolerability of Sodium Thiosulfate in Patients with an Acute Coronary Syndrome Undergoing Coronary Angiography: A Dose-Escalation Safety Pilot Study (SAFE-ACS)

view on PubMed

External links